As Biotechgate data shows, private equity investment rounds of life science companies increased by around 35% in 2021 compared to 2020. Despite venture investments in biotech companies declining slightly in 2021 compared to the strong previous annum, it was still a solid year for the biotech industry in Switzerland. Four of the five biotech companies with the largest venture financing rounds are from the Basel area, with Anaveon AG raising the highest amount of financing (USD 120 million). Numab Therapeutics from the Zurich area raised the second highest amount (USD 111 million) of financing.
Many thanks to our partners in Switzerland – Basel Area Business & Innovation, the Swiss Biotech Association, Life Science Zurich / Canton of Zurich – who contributed to the report.